Cancer Immunology, Immunotherapy

, Volume 52, Issue 11, pp 680–685 | Cite as

On combining antineoplastic drugs with tumor vaccines

Symposium in Writing


Cancer Vaccines Antineoplastic drugs 


  1. 1.
    Arinaga S, Akiyoshi T, Tsuji H (1986) Augmentation of the generation of cell-mediated cytotoxicity after a single does of adriamycin in cancer patients. Cancer Res 46:4213PubMedGoogle Scholar
  2. 2.
    Asavaroengchai W, Kotera Y, Mulé JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 99:931CrossRefPubMedGoogle Scholar
  3. 3.
    Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumor burden. Immunology 65:87PubMedGoogle Scholar
  4. 4.
    Berd D, Maguire HCJ, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572PubMedGoogle Scholar
  5. 5.
    Berd D, Sato T, Cohn H, Maguire HCJ, Mastrangelo MJ (2001) Treatment of metastatic melanoma with autologous hapten-modified melanoma vaccine: regression of pulmonary metastates. Int J Cancer 94:531PubMedGoogle Scholar
  6. 6.
    Chan OTM, Yang L-X (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49:181CrossRefPubMedGoogle Scholar
  7. 7.
    Chuang LT, Lotzová E, Heath J, Cook KR, Heath J, Cook KR, Munkarah A, Morris M, Wharton JT (1994) Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. Cancer Res 54:1286PubMedGoogle Scholar
  8. 8.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850Google Scholar
  9. 9.
    Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN (2002) T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110:185CrossRefPubMedGoogle Scholar
  10. 10.
    Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E (1986) Correlation between adriamycin-induced augmentation of interleukin-2 production and of cell-mediated cytotoxicity in mice. Cancer Res 46:54PubMedGoogle Scholar
  11. 11.
    Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ (1989) Effects of anticancer drugs on the immune system in humans. Semin Oncol 16:230Google Scholar
  12. 12.
    Emens LA, Machiels J-P, Reilly RT, Jaffee EM (2001) Chemotherapy: Friend or foe to cancer vaccines? Curr Opin Mol Ther 3:77PubMedGoogle Scholar
  13. 13.
    Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578PubMedGoogle Scholar
  14. 14.
    Hoover SK, Barrett SK, Turk TMT, Lee T-C, Bear HD (1990) Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol Immunother 31:121PubMedGoogle Scholar
  15. 15.
    Hu H-M, Poehlein CH, Urba WJ, Fox BA (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62:3914PubMedGoogle Scholar
  16. 16.
    Kerckhaert JA, Hofhuis FM, Willers JM (1977) Effects of variation in time and dose of cyclophosphamide injection on delayed-type hypersensitivity and antibody formation. Cell Immunol 29:232PubMedGoogle Scholar
  17. 17.
    Maccubbin DL, Wing KR, Mace KF, Ho RLX, Ehrke J, Mihich E (1992) Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 52:3572PubMedGoogle Scholar
  18. 18.
    Mace K, Mayhew E, Mihich E, Ehrke MJ (1988) Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res 48:130PubMedGoogle Scholar
  19. 19.
    Machiels J-PH, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689PubMedGoogle Scholar
  20. 20.
    Maguire HC Jr, Maibach HI (1961) Effect of cyclophosphamide, 6-mercaptopurine, actinomycin D, and vincaleukoblastine on the acquisition of delayed hypersensitivity (DNCB contact dermatitis) in the guinea-pig. J Invest Derm 37:427Google Scholar
  21. 21.
    Maguire HCJ, Maibach HI (1961) Specific immune tolerance to anaphylactic sensitization (egg albumin) induced in the guinea pig by cyclophosphoramide (cytoxan). J Allergy 32:406Google Scholar
  22. 22.
    Maguire HCJ, Maibach HI, Minisce LWJ (1961) Inhibition of guinea pig anaphylactic sensitization with cyclophosphoramide. J Invest Derm 36:256Google Scholar
  23. 23.
    Manthey CL, Perera P-Y, Salkowski CA, Vogel SN (1994) Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 152:825PubMedGoogle Scholar
  24. 24.
    Mullins DW, Burger CJ, Elgert KD (1999) Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 162:6811PubMedGoogle Scholar
  25. 25.
    Nigam A, Yacavone RF, Zahurak ML, Johns CMS, Pardoll DM, Piantadosi S, Levitsky HI, Nelson WG (1998) Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 12:161PubMedGoogle Scholar
  26. 26.
    Orsini F, Pavelic Z, Mihich E (1977) Increased primary cell-mediated immunity in culture subsequent to adriamycin or danorubicin treatment of spleen donor mice. Cancer Res 37:1719PubMedGoogle Scholar
  27. 27.
    Polak L, Geleick H, Turk JL (1975) Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB. Immunology 28:939PubMedGoogle Scholar
  28. 28.
    Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918PubMedGoogle Scholar
  29. 29.
    Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlie D, Belardelli F (1998) Importance of cyclophosphamide-induced bystander effect on T Cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101:429PubMedGoogle Scholar
  30. 30.
    Reilly RT, Gottlieb MBC, Ercolini AM, Machiels J-PH, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM (2000) HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 60:3569PubMedGoogle Scholar
  31. 31.
    Schiavoni G, Mattei F, Pucchio TD, Santini SM, Bracci L, Belardelli F, Proietti E (2000) Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024PubMedGoogle Scholar
  32. 32.
    Shimizu K, Fields RC, Giedlin M, Mulé JJ (1999) Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci U S A 96:2268CrossRefPubMedGoogle Scholar
  33. 33.
    Taniguchi M, Tada T (1971) Regulation of homocytotropic antibody formation in the rat. IV. Effects of various immunosuppressive drugs. J Immunol 107:579PubMedGoogle Scholar
  34. 34.
    Yoshida S, Nomoto K, Himeno K, Takeya K (1979) Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice. Clin Exp Immunol 38:211PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Department of Surgery, Center for Immunology and ImmunotherapyUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations